Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BO
Bolt Biotherapeutics, Inc. Common Stock
BOLT
Mkt Cap
$7.9M
Volume
9.64K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BO
BOLT
BO
Bolt Biotherapeutics, Inc. Common Stock
BOLT
News
·
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Mkt Cap
$7.7M
Volume
9.64K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Bolt Biotherapeutics announced positive results from a Phase 1 study of its cancer immunotherapy BDC-3042, which showed favorable safety, biological activity, and signs of anti-tumor activity. The company is seeking a partner to advance the development of BDC-3042.
GlobeNewswire Inc. · Apr 25, 2025
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Bolt Biotherapeutics presented positive preclinical data for its next-generation cancer immunotherapy candidate BDC-4182 and key learnings from its Phase 1 trial of BDC-1001, suggesting that enhanced immune activation could lead to greater efficacy.
GlobeNewswire Inc. · Nov 7, 2024
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Bolt Biotherapeutics, Inc. is facing a securities fraud lawsuit alleging that the company made false and misleading statements about the effectiveness of its drug BDC-1001 in treating certain cancers, and overstated the commercial prospects of its drug pipeline.
GlobeNewswire Inc. · Sep 2, 2024
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT
Bolt Biotherapeutics, Inc. is facing a securities class action lawsuit due to allegedly making false and/or misleading statements about the effectiveness of its cancer treatment drug BDC-1001, which could lead to damages for investors.
GlobeNewswire Inc. · Sep 1, 2024
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
A class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (BOLT) alleging that the company made materially false and misleading statements about the effectiveness of its product BDC-1001, overstating its clinical and commercial prospects.
GlobeNewswire Inc. · Aug 30, 2024
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Faruqi & Faruqi, LLP is investigating potential claims against Bolt Biotherapeutics, Inc. (BOLT) for making false and/or misleading statements about its lead asset, BDC-1001, which was less effective than represented and unlikely to meet its success criteria. As a result, Bolt announced it would cease further development of BDC-1001 and reduce its workforce by 50%, leading to a significant stock price drop.
GlobeNewswire Inc. · Aug 30, 2024
BOLT FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT
Rosen Law Firm is encouraging investors of Bolt Biotherapeutics, Inc. to secure counsel before the September 3, 2024 deadline in a securities class action lawsuit. The lawsuit alleges that Bolt made false and/or misleading statements about the effectiveness of its cancer treatment drug BDC-1001.
GlobeNewswire Inc. · Aug 28, 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed class action lawsuits against CVS Health Corporation, Walgreens Boots Alliance, Inc., SeaStar Medical Holding Corporation, and Bolt Biotherapeutics, Inc. The lawsuits allege various issues related to the companies' business operations and financial reporting.
GlobeNewswire Inc. · Aug 27, 2024
רוזן, משרד עורכי דין מוביל לזכויות משקיעים, מעודד את משקיעי Bolt Biotherapeutics, Inc לקבל ייעוץ לפני תאריך יעד חשוב בתביעה ייצוגית בניירות ערך – BOLT
Rosen Law Firm, a leading investor rights law firm, is encouraging investors in Bolt Biotherapeutics, Inc. (BOLT) to seek legal counsel before the important deadline of September 3, 2024 for a securities class action lawsuit. The lawsuit alleges that Bolt made false and misleading statements about the efficacy of its lead drug candidate BDC-1001.
GlobeNewswire Inc. · Aug 24, 2024
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
Rosen Law Firm is encouraging investors of Bolt Biotherapeutics, Inc. to seek legal counsel before the September 3, 2024 deadline for a securities class action lawsuit. The lawsuit alleges that Bolt made false and/or misleading statements about the effectiveness of its cancer treatment drug BDC-1001, leading to investor losses.
GlobeNewswire Inc. · Aug 24, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
BO
BOLT
Bolt Biotherapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
BOLT
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any BOLT yet.
Related Tickers
Earnings